USFDA finds several violations in Aurobindo sterile injections unit

The US Food and Drug Administration has observed several violations and shortcomings in Aurobindo Pharma’s sterile injections facility in Pashamylaram, Hyderabad, in yet another setback for the firm. FDA investigators have observed violations in sterilisation process to prevent microbial contamination and shortcomings in facility management procedures along with lapses in the design of the manufacturing plant. The same unit had come under the FDA radar in March 2018. The inspection at Unit IV from November 4-13 found “procedures designed to prevent microbial contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilisation process,” said the Form 483 ‘inspectional observation’ report. EThas seen a copy of the Form 483 issued to Aurobindo Pharma.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.000983 seconds